Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 7/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039529 | 0.75 | RAB9A (0.38) | CES2CES1 | |
| SCHEMBL4434733 | 0.72 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL6343801 | 0.68 | AAK1 (0.36) | SLC6A3 | |
| SCHEMBL1789282 | 0.67 | CES2 (0.38) | KCNN4SLC6A3CES2CES1 | |
| SCHEMBL26396492 | 0.67 | — | — | |
| SCHEMBL1789283 | 0.66 | CES2 (0.37) | KCNN4SLC6A3CES2CES1 | |
| SCHEMBL25563988 | 0.66 | CES2 (0.37) | KCNN4SLC6A3CES2CES1 | |
| SCHEMBL1017354 | 0.66 | SLC6A3 (0.37) | KCNN4SLC6A3CES2CES1ERN1 | |
| SCHEMBL12077684 | 0.65 | DGAT1 (0.36) | KCNN4SLC6A3CES2CES1 | |
| SCHEMBL12833811 | 0.63 | KCNN4 (0.55) | KCNN4CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625901-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | EDNRB, CALCRL, QRFPR | KCNN4 402/4885SLC6A3 1030/4885CES2 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.